Tickers

1. Composite Trajectory Verdict

For a clinical-stage biopharma with one commercial product (DEXTENZA) and a pivotal Phase 3 pipeline (AXPAXLI), all three statements carry weight: the income statement captures the investment ramp, the cash flow statement measures the burn rate against finite runway, and the balance sheet shows the liquidity cushion from recent equity raises.

Composite Trajectory: Mixed

Revenue is declining on an annual basis (DEXTENZA net product revenue fell 18.3% to $51.8M in 2025 vs $63.5M in 2024) and flat sequentially (Q2 2026 $13.5M vs Q2 2025 $13.4M). Operating losses are widening sharply: FY 2025 loss from operations $(270.0M) vs $(171.8M) in 2024; H1 2026 $(175.5M) vs $(131.6M) in H1 2025. Cash burn is accelerating: operating cash outflow $(204.9M) in FY 2025 vs $(134.7M) in FY 2024, and $(133.3M) in H1 2026 vs $(99.9M) in H1 2025. However, the balance sheet still holds $598.6M cash at June 30, 2026 (down from $737.1M at Dec 31, 2025), and management states this funds operations into 2028. The trajectory is therefore mixed: deteriorating earnings and cash flow offset by a still-substantial liquidity position.

2. Red Flags

• Accelerating cash burn with no recent financing: Operating cash outflow $(133.3M) in H1 2026 vs $(99.9M) in H1 2025; financing inflows only $2.9M in H1 2026 vs $102.0M in H1 2025 (10-Q 2026-06-30, Condensed Statements of Cash Flows). Net cash decreased $138.4M in six months.
• Declining commercial revenue: DEXTENZA net product revenue fell 18.3% YoY to $51.8M in FY 2025 (10-K 2025-12-31, Consolidated Statements of Operations). GTN provisions rose to 51.6% of gross sales in 2025 from 38.5% in 2024, and to 55.0% in Q2 2026 from 51.7% in Q2 2025 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Widening operating losses: Loss from operations $(270.0M) FY 2025 vs $(171.8M) FY 2024 vs $(82.4M) FY 2023 (10-K 2025-12-31, Consolidated Statements of Operations). H1 2026 $(175.5M) vs $(131.6M) H1 2025 (10-Q 2026-06-30, Condensed Statements of Operations).
• Rising R&D and pre-commercial spend: R&D $197.1M FY 2025 vs $127.6M FY 2024; $120.4M H1 2026 vs $93.9M H1 2025. S&M $53.9M FY 2025 vs $41.6M FY 2024; $33.9M H1 2026 vs $27.9M H1 2025 (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Pending litigation: EyePoint, Inc. lawsuit filed March 2026 alleging defamation and commercial disparagement; motion for preliminary injunction hearing held May/July 2026, ruling pending (10-Q 2026-06-30, Note 14).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Deteriorating

Total net revenue declined to $52.0M in FY 2025 from $63.7M in FY 2024 (10-K 2025-12-31, Consolidated Statements of Operations). Product revenue (DEXTENZA) fell 18.3% to $51.8M. In H1 2026, product revenue was essentially flat at $24.3M vs $24.0M in H1 2025 (10-Q 2026-06-30, Condensed Statements of Operations). Total operating expenses rose to $322.0M in FY 2025 from $235.5M in FY 2024, driven by R&D ($197.1M vs $127.6M), S&M ($53.9M vs $41.6M), and G&A ($64.4M vs $60.7M). H1 2026 operating expenses reached $199.7M vs $155.7M in H1 2025. Net loss widened to $(265.9M) FY 2025 from $(193.5M) FY 2024 and $(80.7M) FY 2023; H1 2026 net loss $(167.4M) vs $(131.9M) H1 2025. No collaboration revenue recognized in H1 2026 vs $0.1M in H1 2025.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Operating cash outflow accelerated to $(204.9M) in FY 2025 from $(134.7M) in FY 2024 and $(70.2M) in FY 2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows). In H1 2026, operating cash outflow was $(133.3M) vs $(99.9M) in H1 2025 (10-Q 2026-06-30, Condensed Statements of Cash Flows). Investing cash outflow increased to $(11.9M) FY 2025 (mostly AXPAXLI manufacturing scale-up) and $(8.0M) H1 2026. Financing inflows were large in FY 2025 ($561.7M, primarily $445.6M October offering and $94.0M ATM sales) and FY 2024 ($332.1M private placement), but only $2.9M in H1 2026 (stock options/ESPP). Net cash change: +$345.0M FY 2025, +$196.1M FY 2024, but $(138.4M) in H1 2026. Cash balance fell from $737.1M at Dec 31, 2025 to $598.6M at June 30, 2026.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Cash and cash equivalents decreased to $598.6M at June 30, 2026 from $737.1M at Dec 31, 2025 (10-Q 2026-06-30, Condensed Consolidated Balance Sheets). Total assets declined to $671.3M from $808.1M. Total liabilities slightly decreased to $151.3M from $153.7M; Barings Credit Facility principal unchanged at $82.5M (net carrying value $72.8M vs $71.3M). Derivative liability fell to $10.9M from $13.9M. Stockholders' equity declined to $520.0M from $654.3M, driven by accumulated deficit growing to $(1,324.4M) from $(1,157.0M). Additional paid-in capital increased to $1,844.4M from $1,811.3M from option exercises and stock comp. Minimum liquidity covenant of $20.0M under Barings Credit Agreement observed.

6. Data Gaps

• Full-year 2026 results (only H1 2026 available via 10-Q; 10-K for 2026 not yet filed).
• Q3 2026 and Q4 2026 quarterly data (only Q1 and Q2 2026 in 10-Q 2026-06-30).
• Detailed breakdown of GTN provisions components (OIDs, chargebacks, rebates) beyond aggregate percentages.
• Specific cash interest paid vs non-cash interest expense allocation for H1 2026 (only total cash paid for interest $4.4M shown in cash flow supplemental).
• Outcome of EyePoint litigation (pending as of June 30, 2026).
• Post-June 2026 financing activities (no equity raises disclosed in H1 2026; future ATM or offering capacity not quantified).